GlassScriptPhysician profile
John Gregory Zora
NPI 1518377654
$15,721.83
in general payments reported to CMS, 2019-2025
55 companies · $2,092 in 2025
The $2,092 reported for 2025 was more than what 77% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,002 · 2020: $2,165 · 2021: $2,811 · 2022: $2,815 · 2023: $2,588 · 2024: $2,248 · 2025: $2,092.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,864 · Education: $64.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,863.94 |
| Education | $64.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,589.94 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,967.84 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $1,572.45 | 2019-2025 | Tepezza, Evenity, Prolia |
| Sanofi-Aventis U.S. LLC | $1,487.71 | 2019-2025 | |
| Ibsa Pharma INC. | $794.97 | 2019-2024 | Tirosint, Licart, Licart |
| Corcept Therapeutics | $726.42 | 2019-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $681.34 | 2019-2024 | Jardiance, Tradjenta, Synjardy |
| Tandem Diabetes Care, INC. | $605.10 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amneal Pharmaceuticals LLC | $543.15 | 2019-2025 | Unithroid |
| Xeris Pharmaceuticals, INC. | $525.83 | 2021-2025 | Gvoke Hypopen |
| Abbvie INC. | $466.90 | 2019-2025 | Synthroid |
| Dexcom, INC. | $409.23 | 2020-2024 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $385.37 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $352.29 | 2021-2025 | Strensiq |
| Abbott Laboratories | $298.57 | 2020-2025 | Freestyle Libre 3 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Zora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.